IVI Foundation, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026 Valencia, Spain.
IVI RMA Valencia, 46015 Valencia, Spain.
Cells. 2022 Jun 8;11(12):1867. doi: 10.3390/cells11121867.
Mitochondria transfer techniques were first designed to prevent the transmission of diseases due to mutations in mtDNA, as these organelles are exclusively transmitted to the offspring by the oocyte. Despite this, given the crucial role of mitochondria in oocyte maturation, fertilization and subsequent embryo development, these approaches have been proposed as new potential strategies to overcome poor oocyte quality in infertile patients. This condition is a very common cause of infertility in patients of advanced maternal age, and patients with previous in vitro fertilization (IVF) attempt failures of oocyte origin. In this context, the enrichment or the replacement of the whole set of the oocyte mitochondria may improve its quality and increase these patients' chances of success after an IVF treatment. In this short review, we will provide a brief overview of the main human studies using heterologous and autologous mitochondria transfer techniques in the reproductive field, focusing on the etiology of the treated patients and the final outcome. Although there is no current clearly superior mitochondria transfer technique, efforts must be made in order to optimize them and bring them into regular clinical practice, giving these patients a chance to achieve a pregnancy with their own oocytes.
线粒体转移技术最初是为了防止因 mtDNA 突变而导致的疾病传播而设计的,因为这些细胞器仅通过卵母细胞传递给后代。尽管如此,鉴于线粒体在卵母细胞成熟、受精和随后的胚胎发育中的关键作用,这些方法已被提议作为克服不孕患者卵母细胞质量差的新的潜在策略。这种情况是高龄产妇不孕的一个非常常见的原因,也是卵母细胞来源的先前体外受精(IVF)尝试失败的患者的一个常见原因。在这种情况下,富集或替换整个卵母细胞的线粒体集合可以改善其质量,并增加这些患者在 IVF 治疗后的成功机会。在这篇简短的综述中,我们将简要概述在生殖领域中使用异体和自体线粒体转移技术的主要人类研究,重点关注治疗患者的病因和最终结果。尽管目前没有明显优越的线粒体转移技术,但必须努力优化这些技术并将其纳入常规临床实践,让这些患者有机会用自己的卵母细胞实现妊娠。